Saskia Middeldorp, ASH 2022: The efficacy of low-molecular-weight heparin in women with recurrent miscarriage and inherited thrombophilia – the ALIFE 2 trial
Studies have linked recurrent miscarriage with inherited thrombophilia. The ALIFE 2 trial aimed to assess the efficacy of low-molecular-weight heparin (LMWH) therapy in women with recurrent miscarriage and inherited thrombophilia. In this touchONCOLOGY interview, we speak with Professor Saskia Middeldorp (Radboud University Medical Center, Nijmegen, Netherlands) to discuss the ALIFE 2 clinical trial and the impact the findings have for women with inherited thrombophilia.
The abstract entitled ‘Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial’ (Abstract #LB-5) was presented at ASH Annual Meeting, 10–13, December, 2022.
- What was known about the use of anticoagulants to reduce adverse pregnancy outcomes in women with inherited thrombophilia? (0:18)
- What were the aims, design and eligibility criteria of the ALIFE 2 clinical trial? (2:04)
- What were the primary and secondary outcome measures and how well were they achieved in the two groups? (2:45)
- On the basis of these findings, what advice would you give to women with confirmed inherited thrombophilia, with recurrent pregnancy loss? (4:17)
- What further research is needed? (5:41)
Disclosures: Saskia Middeldorp is on the advisory board and has received honoraria from Aspen, Pfizer and Viatris. She has received grant/research support from Aspen and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed as a highlight of ASH 2022
Access more content on Haematology
Share this Video
Related Videos In Haematology
Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial and when results should be expected. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled […]
Bernd Jilma, ASH 2022: The pathophysiology and unmet treatment needs in cold agglutinin disease
Cold agglutinin disease (CAD) is a rare, autoimmune, clonal B cell disorder. In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the pathophysiology of CAD and the unmet treatment needs in this disease. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study […]
Srdan Verstovsek, ASH 2022: Momelotinib long-term safety in myelofibrosis disease – Analysis of SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials
Momelotinib, an oral JAK1/JAK2/ACVR1 inhibitor, was evaluated in 3 randomised controlled trials – SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, in patients with high- and intermediate-risk myelofibrosis. In this touchONCOLOGY interview, we speak with Prof. Srdan Verstovsek (MD Anderson Cancer Center, Houston, TX, USA) to discuss the limitations of JAK inhibitor therapy in myelofibrosis, and the integrated analysis of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!